Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark T Orr

Showing results (21-30 of 50) with videos related to

Pageof 5
Sort By:
The Journal of Experimental Medicine|April 1, 2009
Ly49H signaling through DAP10 is essential for optimal natural killer cell responses to mouse cytomegalovirus infectionMark T Orr, Joseph C Sun, David G T Hesslein, et al.
Plos One|January 6, 2016
The TLR4 Agonist Vaccine Adjuvant, GLA-SE, Requires Canonical and Atypical Mechanisms of Action for TH1 InductionNatasha Dubois Cauwelaert, Anthony L Desbien, Thomas E Hudson, et al.
Plos One|January 10, 2014
A dual TLR agonist adjuvant enhances the immunogenicity and protective efficacy of the tuberculosis vaccine antigen ID93Mark T Orr, Elyse A Beebe, Thomas E Hudson, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 18, 2018
Effective Combination Adjuvants Engage Both TLR and Inflammasome Pathways To Promote Potent Adaptive Immune ResponsesEmilie Seydoux, Hong Liang, Natasha Dubois Cauwelaert, et al.
The Journal of Infectious Diseases|February 1, 2015
Interferon γ and Tumor Necrosis Factor Are Not Essential Parameters of CD4+ T-Cell Responses for Vaccine Control of TuberculosisMark T Orr, Hillarie Plessner Windish, Elyse A Beebe, et al.
Plos One|December 15, 2010
Development and function of CD94-deficient natural killer cellsMark T Orr, Jun Wu, Min Fang, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 3, 2014
Immune subdominant antigens as vaccine candidates against Mycobacterium tuberculosisMark T Orr, Gregory C Ireton, Elyse A Beebe, et al.
Plos One|March 11, 2021
Prophylactic efficacy against Mycobacterium tuberculosis using ID93 and lipid-based adjuvant formulations in the mouse modelSusan L Baldwin, Valerie A Reese, Sasha E Larsen, et al.
Vaccines|May 26, 2018
Enhanced Anti-<i>Mycobacterium tuberculosis</i> Immunity over Time with Combined Drug and Immunotherapy TreatmentSasha E Larsen, Susan L Baldwin, Mark T Orr, et al.
Blood|April 19, 2011
Mouse Ly49G2+ NK cells dominate early responses during both immune reconstitution and activation independently of MHCIsabel Barao, Maite Alvarez, Erik Ames, et al.
Pageof 5

Showing results (21-30 of 50) with videos related to

Sort By:
Pageof 5
The Journal of Experimental Medicine|April 1, 2009
Ly49H signaling through DAP10 is essential for optimal natural killer cell responses to mouse cytomegalovirus infectionMark T Orr, Joseph C Sun, David G T Hesslein, et al.
Plos One|January 6, 2016
The TLR4 Agonist Vaccine Adjuvant, GLA-SE, Requires Canonical and Atypical Mechanisms of Action for TH1 InductionNatasha Dubois Cauwelaert, Anthony L Desbien, Thomas E Hudson, et al.
Plos One|January 10, 2014
A dual TLR agonist adjuvant enhances the immunogenicity and protective efficacy of the tuberculosis vaccine antigen ID93Mark T Orr, Elyse A Beebe, Thomas E Hudson, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 18, 2018
Effective Combination Adjuvants Engage Both TLR and Inflammasome Pathways To Promote Potent Adaptive Immune ResponsesEmilie Seydoux, Hong Liang, Natasha Dubois Cauwelaert, et al.
The Journal of Infectious Diseases|February 1, 2015
Interferon γ and Tumor Necrosis Factor Are Not Essential Parameters of CD4+ T-Cell Responses for Vaccine Control of TuberculosisMark T Orr, Hillarie Plessner Windish, Elyse A Beebe, et al.
Plos One|December 15, 2010
Development and function of CD94-deficient natural killer cellsMark T Orr, Jun Wu, Min Fang, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 3, 2014
Immune subdominant antigens as vaccine candidates against Mycobacterium tuberculosisMark T Orr, Gregory C Ireton, Elyse A Beebe, et al.
Plos One|March 11, 2021
Prophylactic efficacy against Mycobacterium tuberculosis using ID93 and lipid-based adjuvant formulations in the mouse modelSusan L Baldwin, Valerie A Reese, Sasha E Larsen, et al.
Vaccines|May 26, 2018
Enhanced Anti-<i>Mycobacterium tuberculosis</i> Immunity over Time with Combined Drug and Immunotherapy TreatmentSasha E Larsen, Susan L Baldwin, Mark T Orr, et al.
Blood|April 19, 2011
Mouse Ly49G2+ NK cells dominate early responses during both immune reconstitution and activation independently of MHCIsabel Barao, Maite Alvarez, Erik Ames, et al.
Pageof 5